Preconditioning cell treatment for immunotherapy

This technology is a preconditioning regimen for mesenchymal stem cells prior to immunotherapy.

Unmet Need: Uniform immunomodulatory phenotype for immunotherapy

Mesenchymal stem cells (MSCs) are evolving as a promising cell-based therapy for a wide range of immune-related disorders, as they have been shown to possess immunosuppressive and hypoimmunogenic properties. MSC-based immunotherapy has shown limited efficacy in clinical trials, compared to in vitro studies.. Despite preconditioning methods, the mesenchymal stem cells used for treatment have unstable immunosuppressive action. There is a need for an improved stem cells preconditioning regimen for immunomodulatory and immunosuppressive applications.

The Technology: Cell preconditioning regimen for enhanced immunosuppressive potential

This technology is a method to enhance clinical efficacy of cell-based immunotherapy. It combines two preconditioning methods: exposure to hypoxia and to an inflammatory cytokine, to increase the immunosuppressive potential of mesenchymal stem cells. The dual-treatment priming regimen confers greater cellular improvements and less dependence on oxidative phosphorylation indicative of enhanced immunoregulatory functions and increased therapeutic potential.

This technology has been validated in vitro.

Applications:

  • Preconditioning regimen for cell-based therapies and other stem cell types
  • Research on exosomes and microvesicles from dual-stimulated MSCs
  • Immunosuppressant therapy for transplantation
  • Preconditioning regimen for autoimmune diseases treatment and ischemic heart disease

Advantages:

  • High immunomodulatory potential
  • Increased survival rate and engraft post-injection
  • Cost-effective

Lead Inventor:

Gordana Vunjak-Novakovic, Ph.D.

Patent Information:

Patent Pending

Related Publications:

Tech Ventures Reference: